+

WO1997037029B1 - MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR β RECEPTOR AND METHODS OF USE THEREOF - Google Patents

MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR β RECEPTOR AND METHODS OF USE THEREOF

Info

Publication number
WO1997037029B1
WO1997037029B1 PCT/US1997/004198 US9704198W WO9737029B1 WO 1997037029 B1 WO1997037029 B1 WO 1997037029B1 US 9704198 W US9704198 W US 9704198W WO 9737029 B1 WO9737029 B1 WO 9737029B1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antibody according
pdgf
amino acid
acid sequence
Prior art date
Application number
PCT/US1997/004198
Other languages
French (fr)
Other versions
WO1997037029A1 (en
Filing date
Publication date
Priority claimed from US08/621,751 external-priority patent/US5882644A/en
Application filed filed Critical
Priority to AU23298/97A priority Critical patent/AU2329897A/en
Publication of WO1997037029A1 publication Critical patent/WO1997037029A1/en
Publication of WO1997037029B1 publication Critical patent/WO1997037029B1/en

Links

Abstract

The invention relates to monoclonal antibodies, humanized monoclonal antibodies and functional derivatives thereof specific for the platelet-derived growth factor receptor β. Methods of use of the antibody, particularly in ameliorating restenosis, are also provided.

Claims

AMENDED CLAIMS[received by the International Bureau on 12 November 1997 (12.11.97); original claim 1 amended; remaining claims unchanged (1 page)]
1. An antibody that specifically binds to the PDGF beta receptor not within the fifth extracellular Ig-like domain, wherein the antibody inhibits PDGF BB-induced proliferation of a cell expressing the PDGF beta receptor, and where the inhibition is greater than about 80% and is achieved at an antibody concentration of no greater than about 10 μg/ml.
2. The antibody according to claim 1 , wherein the antibody inhibits binding of PDGF BB to a cell expressing the PDGF beta receptor.
3. The antibody according to claim 1 , wherein the antibody binds to the third extracellular Ig-like domain of the PDGF beta receptor.
4. The antibody according to claim 2, wherein the antibody is muM4TS.22.
5. The antibody according to claim 2, wherein the antibody is humanized.
6. The antibody according to claim 5, wherein the antibody comprises a light chain variable region which has a mature amino acid sequence substantially identical to the mature amino acid sequence of Figure 2B (SEQ ID NO:6) and a heavy chain variable region which has an amino acid sequence substantially identical to the mature amino acid sequence of Figure 2D (SEQ ID NO:8).
7. The antibody according to claim 6, wherein the antibody is HuM4TS.22.
8. Substantially isolated polynucleotide sequences that encode an antibody according to claim 6 and polynucleotide sequences complementary thereto.
9. The antibody according to claim 1, wherein the antibody does not inhibit binding of PDGF BB to a cell expressing the PDGF beta receptor.
10. The antibody according to claim 1 , wherein the antibody binds to the fourth extracellular Ig-like domain of the PDGF beta receptor.
1 1. The antibody according to claim 9, wherein the antibody is muM4TS.1 1.
12. The antibody according to claim 9, wherein the antibody is humanized.
13. The antibody according to claim 12, wherein the antibody comprises a light chain variable region which has a mature amino acid sequence substantially identical to the mature amino acid sequence of Figure 8B (SEQ ID NO: 14) and a heavy chain variable
-67-
PCT/US1997/004198 1996-03-22 1997-03-19 MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR β RECEPTOR AND METHODS OF USE THEREOF WO1997037029A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23298/97A AU2329897A (en) 1996-03-22 1997-03-19 Monoclonal antibodies specific for the platelet derived growth factor beta receptor and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/621,751 US5882644A (en) 1996-03-22 1996-03-22 Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US08/621,751 1996-03-22

Publications (2)

Publication Number Publication Date
WO1997037029A1 WO1997037029A1 (en) 1997-10-09
WO1997037029B1 true WO1997037029B1 (en) 1997-12-18

Family

ID=24491483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004198 WO1997037029A1 (en) 1996-03-22 1997-03-19 MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR β RECEPTOR AND METHODS OF USE THEREOF

Country Status (3)

Country Link
US (1) US5882644A (en)
AU (1) AU2329897A (en)
WO (1) WO1997037029A1 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US20020044933A1 (en) * 1993-02-25 2002-04-18 Hart Charles E. Inhibition of intimal hyperplasia using antibodies to PDGF receptors
US6114110A (en) * 1996-01-16 2000-09-05 University Of Michigan Isolation and propagation of a human herpesvirus derived from AIDS-associated Kaposi's sarcoma cells
AU6497198A (en) * 1997-02-14 1998-09-08 Boehringer Mannheim Gmbh Improved method for the reduction of neointima formation after angioplasty
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
ITMI20002832A1 (en) * 2000-12-27 2002-06-27 Acetum S R L BALSAMIC SAUCE FOR FOOD USE BASED ON BALSAMIC VINEGAR OF MODENA
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
WO2003063575A2 (en) * 2002-01-29 2003-08-07 Colb A Mark Endothelialization of vascular surfaces
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
CA2536912C (en) 2003-08-27 2015-03-31 Eyetech Pharmaceuticals, Inc. Combination therapy for the treatment of ocular neovascular disorders
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
EP1735011A4 (en) * 2004-04-16 2008-03-26 Scripps Research Inst METHOD FOR MODULATING VASCULARIZATION
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR20140087058A (en) 2005-11-30 2014-07-08 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
CL2007002225A1 (en) * 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
WO2008070344A2 (en) 2006-10-27 2008-06-12 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) * 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
JP5209702B2 (en) * 2007-04-17 2013-06-12 イムクローン・リミテッド・ライアビリティ・カンパニー PDGFRβ specific inhibitor
EP2144930A1 (en) * 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
ES2585702T3 (en) * 2007-05-30 2016-10-07 Lpath, Inc Compositions and methods for lysophosphatidic acid binding
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US9273134B2 (en) 2007-06-05 2016-03-01 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
CA2716882A1 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfr-beta and vegf-a
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
CN102573905A (en) * 2008-12-05 2012-07-11 勒帕斯公司 Antibody design using anti-lipid antibody crystal structures
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400981A4 (en) * 2009-02-26 2013-02-27 Lpath Inc Humanized platelet activating factor antibody design using anti-lipid antibody templates
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
EP2419446A4 (en) * 2009-04-17 2013-01-23 Lpath Inc Humanized antibody compositions and methods for binding lysophosphatidic acid
UY32914A (en) 2009-10-02 2011-04-29 Sanofi Aventis ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
US8754195B2 (en) 2010-07-02 2014-06-17 Medimmune, Llc Antibody formulations
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
DK2668210T3 (en) 2011-01-26 2020-08-24 Celldex Therapeutics Inc ANTI-KIT ANTIBODIES AND USES THEREOF
JP2014519813A (en) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー Use of EMT gene signatures in cancer drug discovery, diagnosis, and treatment
TWI613215B (en) 2012-02-22 2018-02-01 再生元醫藥公司 Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
JO3405B1 (en) 2013-01-09 2019-10-20 Regeneron Pharma ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
DK3041513T3 (en) 2013-09-08 2020-10-26 Kodiak Sciences Inc ZWITTERIONIC FACTOR VIII POLYMER CONJUGATES
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3161000A4 (en) * 2014-06-28 2018-05-02 Kodiak Sciences Inc. Dual pdgf/vegf antagonists
KR20210013299A (en) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 Butyrylcholinesterase zwitterionic polymer conjugates
JP2018517660A (en) 2015-03-20 2018-07-05 ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン Pericyte long noncoding RNA
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
CN110945023B (en) 2017-07-31 2023-08-18 豪夫迈·罗氏有限公司 Three-dimensional structure-based humanization method
KR20200140817A (en) 2018-03-02 2020-12-16 코디악 사이언시스 인코포레이티드 IL-6 antibodies and fusion constructs and conjugates thereof
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
EP3856343A1 (en) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
JP2022553640A (en) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド Methods of treating eye disorders
CN115427447B (en) 2020-01-17 2025-02-18 百进生物科技公司 Anti-TLR 7 agents and compositions and methods of making and using the same
CA3170712A1 (en) * 2020-02-07 2021-08-12 Biorion Technologies B.V. Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof.
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
CN119968395A (en) 2022-08-18 2025-05-09 百进生物科技公司 Anti-AXL antibodies, antigen-binding fragments thereof, and methods of making and using the same
WO2024243217A1 (en) 2023-05-25 2024-11-28 BioLegend, Inc. Ceacam6 binding antibodies and antigen-binding fragments thereof
WO2025072313A1 (en) 2023-09-27 2025-04-03 BioLegend, Inc. Anti-gpc4 antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) * 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4754065A (en) * 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
PL171920B1 (en) * 1991-12-02 1997-06-30 Cor Therapeutics Inc Method of obtaining a novel immunoglobulin polypeptide capable to inhibit pdgf-r
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
EP0686044B1 (en) * 1993-02-25 1998-09-02 ZymoGenetics, Inc. Inhibition of intimal hyperplasia using antibodies to pdgf receptors

Similar Documents

Publication Publication Date Title
WO1997037029B1 (en) MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR β RECEPTOR AND METHODS OF USE THEREOF
Banerjee et al. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin.
Soncin et al. Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells
Bayer et al. [4] Biotin-binding proteins: Overview and prospects
WO1998050431A3 (en) A method for making multispecific antibodies having heteromultimeric and common components
CA2128784C (en) Large, latent complexes of tgf-beta2 and tgf-beta3
EP0930366A3 (en) Binding domains in delta proteins
CA2373274A1 (en) Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
TWI318983B (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
NZ507557A (en) Protein purification by ion exchange chromatography
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
UA40621C2 (en) monoclonal antibody, hybridoma cell line, polypeptide (VARIANTS), THE DNa FRAGMENT (VARIANTS), PHARMACEUTICAL COMPOSITION, METHOD FOR preparation OF monoclonal antibody
CA2189657A1 (en) Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
IL181578A0 (en) Antibodies which are specifically immunoreactive with hedgehog interacting proteins and a hybridoma producing such antibodies
JPH03204896A (en) Extracellular fragment of interferon receptor
CA2471762A1 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2000023565A3 (en) Novel neuropilin/growth factor binding and uses thereof
MX9702422A (en) Dna encoding the variable region of monoclonal antibody and recombinant antibody.
WO1995000552B1 (en) Prostaglandin receptor ep3 and dna encoding it
CA2133873A1 (en) Tnf inhibitors
WO1999046386B1 (en) ALK-1 RESPONDS TO TGF-β AND SIGNALS THROUGH SMAD-1 AND SMAD-5
WO1999048908A3 (en) NGF TrkA RECEPTOR IMMUNOREACTIVE POLYPEPTIDE AND USES
Wood et al. Identification of Limulus polyphemus haemocyanin messenger RNA
CA2180957A1 (en) Cloning and recombinant production of crf receptor(s)
Lebovitz et al. The Amino Acid Sequence of the Fc Fragment of Rabbit Immunoglobulin G: I. THE ISOLATION AND AMINO ACID COMPOSITION OF TRYPTIC PEPTIDES
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载